Editor-The editorial by Aronson et al raises important concerns about the preparedness of newly qualified doctors to prescribe safely and effectively, but fails to provide evidence to support the claims that are made.
Summary of responses
Many of the 18 other responses to the editorial by Aronson et al (mainly from UK based doctors and pharmacists) emphasised the importance of teamwork and communication as key to improving prescribing. 1 The dean of the University of East Anglia Medical School, Sam Leinster, and his pharmacology lecturer colleague Yoon Loke were, however, concerned that the editorial had drawn conclusions about the quality of teaching before the data had been collected and evaluated.
Proposed solutions to the perceived problem include drawing on the skills of (clinical) pharmacists or nurse practitioners; separating the disciplines of diagnosis and prescription and using two different professionals ("diagnosticians" and "therapeuts"); using prescribing advisers in primary care trusts or specially trained clinical pharmacologists; gaining additional postgraduate certifications; making decision aids available through information technology, on personal digital assistants, or in the shape of the (electronic) BNF or Drugs and Therapeutics Bulletin . . . The list goes on: additional training shifts on the wards for senior medical students and increased or prolonged supervision of student doctors by different types of professionals.
By way of improving training, a programme of teaching and reflective learning has been developed at the University of Dundee Medical School, the Appropriate Prescribing for Tomorrow's Doctors project. Developed by specialists in infection and medical education, it has now been adopted by medical schools throughout the UK. The programme's primary resource is an interactive website with access to clinical worked examples, prescribing exercises, self assessment tools, and a reflective learning logbook.
London based primary care professor Azeem Majeed and colleagues discuss the topic of admissions to hospital as a result of adverse drug reactions-a possible consequence of poor prescribing-and conclude that we do not have good enough data to draw conclusions on how to improve prescribing, something that Nicholas Moore, professor of clinical pharmacology in France, echoes but thinks that any admission for an adverse reaction is reason to try to improve the practice of prescribing. D B Double, consultant psychiatrist in Norfolk, looks at the issue from another angle, arguing that overprescribing may be as much a problem as underprescribing. Doctors need to focus on the patient to get it right, as not every patient may be after a prescription in the first place.
Bevan 
Preventing and detecting early vascular effects of diabetes
Improvement must continue or costs will escalate
Editor-As editor of a diabetic retinopathy website with patients regulary sending letters, I agree with Marshall and Flyvberg's comments. 1 Care is rapidly improving across the United Kingdom, but around a quarter of patients with retinopathy still present with severe retinopathy at time of diagnosis of diabetes. They have not been screened for diabetes, despite having it for 5-10 years and having been recommended screening by medical professionals. 2 Thus, in addition to Marshall and Flyvberg's suggestions, screening for diabetes itself must improve if retinopathy is to be prevented; and people must make the lifestyle changes to avoid type 2 diabetes. 3 If control of diabetes improves from a poor level yielding a significantly lower HbA 1c , however, well established retinopathy may progress rapidly: good control will help in the long but not the short term. This has played a part in worsening severe retinopathy in many people.
Basal bolus insulin regimens may reduce retinopathy progression compared with twice daily regimens, even in type 2 diabetes (A Liebl et al, American Diabetes Association 66th annual scientific sessions, Washington, DC, June 2006), yet regimens of insulin twice daily remain popular.
New and effective drugs are about to be launched to treat diabetic retinopathy. Results of treatment should improve tremendously, but the cost of the drugs might help to bankrupt the NHS unless there are fewer patients to treat (£3000-6000 (€4402-8804, $5595-11 191) per course). 
Word of caution on peripheral arterial assessment
Editor-Marshall and Flyvbjerg's clinical review gives contradictory information about measuring the ankle-brachial pressure ratio in diabetic patients, as well as portraying an unrealistic picture of the assessment of peripheral arterial disease in them. Firstly, 10-15% of diabetic patients may have a falsely raised ankle-brachial pressure ratio because early calcification of the tunica media renders the arteries incompressible. 2 This should not be solely relied on as an objective assessment criterion. The pole test is more accurate. 3 The arteries of the foot and toes are comparatively spared in diabetes. Therefore other tests-such as the toe pressure index, analysis of Doppler wave form, pulse volume analysis, and transcutaneous oxygen measurements-are far better but can rarely be done outside specialist clinics.
Secondly, for practical reasons the ankle-brachial pressure ratio should be measured at the peroneal (fibular) artery rather than the posterior tibial artery or dorsalis pedis, as mentioned in the clinical review. The peroneal artery in the leg is also comparatively spared from calcification and thus offers the best available option. 3 Thirdly, the review mentions identifying four "classic" risk factors for developing problems with the diabetic foot, but these often blur the picture. Symptoms such as pain in the foot or leg while resting or during sleep indicate critical ischaemia in patients without diabetes, but diabetic patients have a higher incidence of nocturnal muscle cramping, which is not due to arterial insufficiency. Assessment of pulse in an oedematous, ulcerated foot may not be possible, and infection of foot ulcers because of neuropathy often masks the subtle signs of arterial insufficiency-such as changes in skin colour associated with raising or lowering the foot. 4 Early referral to a specialist multidisciplinary team is essential to reduce complications such as amputation. The interplay of all contributing factors needs to be considered carefully, rather than simply relying on just one test or pressure readings in diabetic patients. 
Saurabh Rai vascular research fellow

Rare diseases need a generic approach
Editor-Dunkelberg describes the experience of looking after her child with a rare disease and an unknown diagnosis. 1 These experiences are all too common in people with rare disease and their families. A survey by the European Organisation for Rare Diseases (Eurordis) in 2005 showed that 25% of people with one of eight rare diseases experienced delayed diagnosis.
2 Forty five per cent had their diagnosis communicated unsatisfactorily, and common problems were experienced by patients with diverse diagnoses. It also estimates that 6-8% of people in Europe have a rare disease. 3 Anecdotally, general practitioners are known to see people with rare diseases often, 4 but there is no published information about the role of primary care in rare diseases. A generic approach is needed to people with rare disease that will avoid some of the problems commonly experienced by patients. We welcome comments on our proposed outline 5 and how the common problem of rare disease should be managed in general practice. It's time for a discussion to start. 
Role of cholinesterase inhibitors in dementia care
Memory clinics and cholinesterase inhibitors have their place
Editor-Pelosi et al ask that the roles of cholinesterase inhibitors and particular components of services for people with dementia be placed in perspective and their value recurrently evaluated as new approaches are identified.
1
As the authors confirm, memory clinics do more than prepare patients for treatment with a cholinesterase inhibitor: they encourage early identification of memory problems, provide high quality investigation and diagnosis, offer education and counselling for patients and families, contribute to the education of caring professionals, and contribute to research and audit. They are rated highly by patients, carers, and referring agencies and are recognised internationally as quality markers in services. 2 In addition, the new generation of clinics are fully integrated into community oriented services for older people, with the specialist knowledge and skills of the clinic team being drawn on and appreciated by the wider group of service providers, as well as patients and carers. 3 4 The general principles of good modern community services for dementia have developed in 30 years. 5 Cholinesterase inhibitors have modest beneficial effects and, in practice, are prescribed, after careful assessment, to comparatively few patients. In our experience, roughly 300 out of the potential 2000 people with dementia from a population of 40 000 older people are receiving such treatment at any one time, and most do not continue with it beyond two years. Expenditure on this treatment is therefore low compared with the overall cost of care for people with dementia from the whole population. The clinic team usually amounts to one or two full time staff, supported on clinic days (one or two days a week) by others with specialist skills, and is small in comparison with the total number of people concerned with the multiagency, multidisciplinary complex care devoted to dementia.
Pelosi et al raise important points. We would like to have even more to offer to people with dementia and their families.
NICE's economic analysis has limitations
Editor-We have concerns with some of the points raised by Pelosi et al in accepting the economic model used by the National Institute for Health and Clinical Excellence (NICE) for its current draft guidance on cholinesterase inhibitors.
1 There are serious and acknowledged limitations and uncertainties in the economic analysis performed by NICE. 2 The model developers admit the model structure to be limited, illustrative, and a crude representation of disease progression. 3 Furthermore, they agree that the evidence base in these areas and across Alzheimer's disease generally is sparse and provides little assistance to analysts undertaking economic evaluations. 4 The current NICE guidance forms the framework in which patients are treated with cholinesterase inhibitors and should form the basis for assessment of cost effectiveness. However, the model did not reflect this. Following comments received during the appraisal, NICE requested manufacturers of cholinesterase inhibitors to produce responder analyses based on its 2001 guidance. These analyses showed improved clinical benefit and cost effectiveness in patients who respond to treatment. NICE subsequently rejected these analyses, although it had asked for them. Similarly NICE has not justified including the costs of treatment for all patients (irrespective of response) for the five years covered by the model. The cost and quality of life data used in the model were unreliable. Cost data seem not to have been indexed. 5 The cost effectiveness values reported by NICE show that the estimates are highly sensitive to small changes in inputs. However, NICE has refused to provide an open model for public scrutiny, and so the robustness of the model cannot be independently tested.
We are concerned that NICE has based an important healthcare decision on flawed economic analysis, and Pelosi et al should have highlighted the serious limitations of the economic analysis.
